Document is current

Article History

Received: 8 May 2025

Accepted: 17 October 2025

First Online: 21 November 2025

Declarations

:

: Philipp Ivanyi: Employment or Leadership Position: Medical Oncology, Hannover Medical School. Advisory Role or Expert Testimony: Bayer, Bristol Myers Squibb, Böhringer Ingelheim, ClinSol, Calliditas, Deciphera, EISAI, EMD-Serono, EUSA, Glaxo Smith Kline, H5-Oncology, Ipsen, Merck Serono (Global), Metaplan, MSD, Novarits, Onkowissen, Pharma Mare, Pfizer, Roche. Stock Ownership: BB-Biotec. Honoraria: AIM, Apogepha, AstraZeneca, Astella, Bayer (+ Europe, Global), Bristol Myers Squibb, CORE2ED, Deciphera, DKG-Onkoweb, EISAI, EUSA, FoFM, Id-Institut, Ipsen (Europe), Merck Serono (+ Europe, Global), Merck Sharp & Dohme, MedKom, MTE-Academy, MedWiss, New Concept Oncology, Onkowissen-tv.de, Pharma Mare, Pfizer, Roche, ThinkWired!, Schmitz-Communikation, StreamedUP!, Solution Academy, Vivantis. Financing of Scientific Research: AIO, AstraZeneca, Bristol Myers Squibb, Calliditas, Cantata, EUSA, EISAI, GlaxoSmithKline, Ipsen, Lilly, Merck, Merck Sharp & Dohme, Niedersächsische Krebsgesellschaft, Novartis, Pfizer, Roche, Serono, Stiftung Immunonkologie, Wilhelm Sander Stiftung. Other Financial Relationships: Bayer, BB-Biotech, Bristol Myers Squibb, Deutsche Gesellschaft für Thoraxchirurgie, EUSA, Ipsen, Merck, Pharma Mare. Immaterial Conflicts of Interest: Member of German Working Party Medical Oncology (AIO), Member of the German Cancer Society, ASCO Member, ESMO Member, Member of Oncological Working Party Hannover (OAK), Spokesman Interdisciplinary Working Party – Kidney Cancer (IAGN-DKG) (non-financial), Leading Group Head and Neck Cancer (Working party German Medical Oncologist (AIO)), IDMC Trial Adam, Steering Board Immunooncology Cooperative Group (ICOG-H), Clinical Trial Steering Committee CCC-H. Konrad Klinghammer: Honoria, Consulting or Advisory role: MSD, Merck Serono, BMS, Roche, Novartis; Boehringer ingelheim, astellas, gsk, Biontech. Travel, accommodation, expenses: Merck, BMS, MSD, Biontech. Research funding: GSK, Merck Serono. Jonas Paul Wiegmann: Travel, accommodation, expenses: AVEO, MSD. Tabea Fröhlich: Honoria, Consulting or Advisory role: Merck, Incyte, Travel, accommodation, expenses: Merck, Immaterial Conflicts of Interest: Member of German Working Party Medical Oncology (AIO), Member of the German Cancer Society, ESMO Member, Coordinator Immunooncology Cooperative Group (ICOG-H), Clinical Trial Steering Committee CCC-H.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

: Lydia Alborn, managing Editor of  Oncology and Therapy , assisted with the recording and editing of this podcast, and provided English language editing of the transcript for clarity. The initial podcast transcript was drafted  by AI and has undergone human editing for accuracy and quality assurance purposes. The transcript itself was further edited for written clarity.